Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 16.24% is 30% above its 5-year average of 12.46%, near the high end of its 5-year range (0.00%–16.24%).
As of the fiscal period ended Tuesday, June 30, 2026. 16.93% above its 12-month average of 13.89%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 16.24%.
DEBT TO ASSETS RATIO
16.24%
DEBT TO ASSETS RATIO AVG TTM
13.89%
DEBT TO ASSETS RATIO AVG 3Y
13.16%
DEBT TO ASSETS RATIO AVG 5Y
12.46%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+16.93%
CURRENT VS 3Y AVG
+23.39%
CURRENT VS 5Y AVG
+30.39%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+17946.81%
vs the sector median at left
Entrada Therapeutics, Inc.
Market Cap
$210.21M
Debt to Assets Ratio
16.24%
TTM Avg
13.89%
3Y Avg
13.16%
5Y Avg
12.46%
Market Cap
$209.05M
Debt to Assets Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$206.37M
Debt to Assets Ratio
0.03%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$214.10M
Debt to Assets Ratio
0.12%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$206.24M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$214.63M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$214.64M
Debt to Assets Ratio
0.09%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | $210.21M | 16.24% | 13.89% | 13.16% | 12.46% |
| Compugen Ltd. (CGEN)vs › | $211.33M | 0.02% | N/A | N/A | N/A |
| Electra Therapeutics Inc. (ETRA)vs › | $209.05M | N/A | N/A | N/A | N/A |
| Pro-Dex, Inc. (PDEX)vs › | $208.17M | 0.24% | N/A | N/A | N/A |
| Sionna Therapeutics, Inc. (SION)vs › | $206.37M | 0.03% | N/A | N/A | N/A |
| Lyell Immunopharma, Inc. (LYEL)vs › | $214.10M | 0.12% | N/A | N/A | N/A |
| Whitehawk Therapeutics Inc (WHWK)vs › | $206.24M | 0.00% | N/A | N/A | N/A |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $214.63M | 0.00% | N/A | N/A | N/A |
| Prelude Therapeutics Incorporated (PRLD)vs › | $214.64M | 0.09% | N/A | N/A | N/A |
| Niagen Bioscience Inc (NAGE)vs › | $214.64M | 0.02% | N/A | N/A | N/A |
Debt/Assets
16.2%
Debt/Equity
0.21
Current Ratio
10.89
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 16.24% |
| 2026-03-31 | 14.83% |
| 2025-12-31 | 13.50% |
| 2025-09-30 | 12.69% |
| 2025-06-30 | 12.20% |
| 2025-03-31 | 11.72% |
| 2024-12-31 | 11.25% |
| 2024-09-30 | 11.06% |
| 2024-06-30 | 11.07% |
| 2024-03-31 | 13.00% |
| 2023-12-31 | 14.54% |
| 2023-09-30 | 14.24% |
| 2023-06-30 | 14.78% |
| 2023-03-31 | 3.41% |
| 2022-12-31 | 10.29% |
| 2022-09-30 | 10.18% |
| 2022-06-30 | 10.11% |
| 2022-03-31 | 10.06% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2020-12-31 | 0.00% |
